A Double Observational Studies Research on the Advantages of Plerixafor for Mobilising Peripheral Blood Stem Cells before Autologous Transplantation
Received Date: May 01, 2023 / Published Date: May 29, 2023
Abstract
Hematopoietic stem cells must be propelled from the bone marrow to the peripheral circulation for collecting prior to autologous stem cell transplantation (ASCT). Plerixafor, an antagonist of C-X-C chemokine receptor type 4, is employed to boost stem cell harvests. Plerixafor's impact on post-ASCT results, however, is still unknown.
Citation: Barkey K (2023) A Double Observational Studies Research on theAdvantages of Plerixafor for Mobilising Peripheral Blood Stem Cells beforeAutologous Transplantation. Arch Sci 7: 155. Doi: 10.4172/science.1000155
Copyright: © 2023 Barkey K. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
Open Access Journals
Article Tools
Article Usage
- Total views: 366
- [From(publication date): 0-2023 - Aug 16, 2024]
- Breakdown by view type
- HTML page views: 313
- PDF downloads: 53
